The Role of Cannabinoids in Chronic Pain Patients Remains Hazy

Chen, B C; Hoffman, Robert S.

doi:10.1038/clpt.2012.27

Cited by 5 publications

(2 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To date, laws still differ considerably from state to state, and even among countries, with much ambiguity regarding what constitutes acceptable medical use and guidelines for such usage. [27][28][29][30] In the USA, the DEA laws, as determined by the Controlled Substances Act (CSA), still classifies cannabis as a Schedule I drug, the most tightly restricted category, reserved for drugs which have no currently accepted medical value and considered too dangerous for use even under medical supervision. Thus there is no uniform set of quality control standards in place to assure the quality, consistency, and availability of medicinal cannabis for patients with chronic pain.…”

Section: The Legal Side Of the Equationmentioning

confidence: 99%

Re-Branding Cannabis: The Next Generation of Chronic Pain Medicine?

Carter

Javaher²,

Nguyen

et al. 2014

Pain Manag.

View full text Add to dashboard Cite

The field of pain medicine is at a crossroads given the epidemic of addiction and overdose deaths from prescription opioids. Cannabis and its active ingredients, cannabinoids, are a much safer therapeutic option. Despite being slowed by legal restrictions and stigma, research continues to show that when used appropriately, cannabis is safe and effective for many forms of chronic pain and other conditions, and has no overdose levels. Current literature indicates many chronic pain patients could be treated with cannabis alone or with lower doses of opioids. To make progress, cannabis needs to be re-branded as a legitimate medicine and rescheduled to a more pharmacologically justifiable class of compounds. This paper discusses the data supporting re-branding and rescheduling of cannabis.

show abstract

Section: The Legal Side Of the Equationmentioning

confidence: 99%

Re-Branding Cannabis: The Next Generation of Chronic Pain Medicine?

Carter

Javaher²,

Nguyen

et al. 2014

Pain Manag.

View full text Add to dashboard Cite

show abstract

“…To the Editor: Thank you for the opportunity to reply to Drs Chen and Hoffman's letter entitled “The Role of Cannabinoids in Chronic Pain Patients Remains Hazy.” 1 The authors are concerned that our data do not justify suggesting that cannabinoids added to opioids did, in fact, produce a pharmacodynamic effect because the sample size was too small to assess the impact of the combination on a clinical outcome. Our study was designed as a pharmacokinetic interaction study, with the main outcome being plasma concentrations over time.…”

mentioning

confidence: 93%

Response to “The Role of Cannabinoids in Chronic Pain Patients Remains Hazy”

Abrams

Couey

Shade

et al. 2012

Clin Pharmacol Ther

View full text Add to dashboard Cite

Vortioxetine: A Review of Its Use in Major Depressive Disorder

Garnock-Jones

2014

CNS Drugs

View full text Add to dashboard Cite

Vortioxetine (Brintellix(®)) is a serotonin (5-HT) transporter inhibitor that also acts on several 5-HT receptors, such as the 5-HT3 and 5-HT1A receptors. It is approved in the US and the EU for the treatment of adult patients with major depressive disorder (MDD); this article reviews the pharmacological properties of oral vortioxetine and its clinical efficacy and tolerability in these patients. Vortioxetine is generally efficacious in patients with MDD in acute treatment trials (including elderly patients), in a relapse-prevention trial, and in open-label extension trials. It is associated with improved cognitive function in patients with MDD; this does not occur solely via improvement in depressive symptom severity. It is well tolerated, but is associated with significantly increased sexual dysfunction at the highest dosage; however, vortioxetine was shown to improve previous-treatment-emergent sexual dysfunction in patients with well-treated MDD to a greater degree than escitalopram. Vortioxetine extends the available treatment options for patients with MDD, and further investigation into its comparative efficacy versus other antidepressants will allow for more accurate placement among these treatment options.

show abstract

The Role of Cannabinoids in Chronic Pain Patients Remains Hazy

Cited by 5 publications

References 5 publications

Re-Branding Cannabis: The Next Generation of Chronic Pain Medicine?

Re-Branding Cannabis: The Next Generation of Chronic Pain Medicine?

Response to “The Role of Cannabinoids in Chronic Pain Patients Remains Hazy”

Vortioxetine: A Review of Its Use in Major Depressive Disorder

Contact Info

Product

Resources

About